Trial Profile

Safety and efficacy study of glucarpidase for delayed clearance of methotrexate after administration of high-dose methotrexate

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glucarpidase (Primary)
Indications Chemotherapy-induced damage
Focus Pharmacokinetics
Acronyms CPG2-PII

Most Recent Events

01 Jul 2024 Results published in the Cancer Chemotherapy and Pharmacology.
28 Sep 2021 According to BTG Specialty Pharmaceuticals media release, Ohara Pharmaceutical Co., Ltd. has obtained marketing authorization for glucarpidase from Japan's Ministry of Health, Labour and Welfare as a therapeutic agent for "detoxication in case of delayed methotrexate elimination with methotrexate-leucovorin rescue therapy," based on the efficacy and safety results of this study.
02 Jul 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com